- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03777462
Borderline Resectable Pancreatic Cancer Neoadjuvant Chemoradiotherapy Clinicaltrial-1 (BRPCNCC-1)
August 31, 2023 updated by: Guo ShiWei, Changhai Hospital
Comparisons of Different Neoadjuvant Chemotherapy Regimens With or Without Stereotactic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer: Study Protocol of a Prospective, Randomized Phase II Trial
This study is to investigate whether neoadjuvant chemotherapy plus SBRT results in better outcomes compared with neoadjuvant chemotherapy alone and also compare the efficacy of gemcitabine plus nab-paclitaxel with SBRT and S-1 plus nab-paclitaxel with SBRT.
Study Overview
Status
Recruiting
Conditions
Detailed Description
This research study is a Phase II clinical trial that investigate whether neoadjuvant chemotherapy plus SBRT results in better outcomes compared with neoadjuvant chemotherapy alone and also compare the efficacy of gemcitabine plus nab-paclitaxel with SBRT and S-1 plus nab-paclitaxel with SBRT.
It is known that neoadjuvant therapy is vital for improved survival, which has been confirmed in previous studies that neoadjuvant chemotherapy with or without radiotherapy provides superior overall compared with upfront surgery.
However, question of whether the addition of radiotherapy to neoadjuvant chemotherapy can improve prognosis compared with chemotherapy alone is a challenging matter.
Also, no studies have evaluated the efficacy of S-1 as the neoadjuvant chemotherapy regimen for BRPC albeit similar prognosis has been found between S-1 and gemcitabine in advanced pancreatic cancer.
In this trial, patients with biopsy and radiographically confirmed BRPC will be randomly allocated into three groups: neoadjuvant gemcitabine plus nab-paclitaxel, neoadjuvant gemcitabine plus nab-paclitaxel with SBRT and neoadjuvant S-1 plus nab-paclitaxel with SBRT.
Surgical resection will be performed 3 weeks after SBRT.
The primary endpoint is overall survival.
The secondary outcomes are progression free survival, pathological complete response rate, R0 resection rate and incidence of adverse effects.
If results show the survival benefits of neoadjuvant chemotherapy plus SBRT and similar outcomes between S-1 and gemcitabine, it may provide evidence of clinical practice of this modality for BRPC.
Study Type
Interventional
Enrollment (Estimated)
150
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Shiwei Guo, Doctor
- Phone Number: +8618621500666
- Email: gestwa@163.com
Study Contact Backup
- Name: Suizhi Gao, Master
- Phone Number: +8613167137990
- Email: gaosuizhi@163.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200433
- Recruiting
- Changhai Hospital
-
Contact:
- Shiwei Guo, Doctor
- Phone Number: +8618621500666
- Email: gestwa@163.com
-
Contact:
- Suizhi Gao, Master
- Phone Number: +8613167137990
- Email: gaosuizhi@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age≥18 years old and ≤80 years old;
- Histological proven pancreatic adenocarcinoma;
- Borderline resectable pancreatic cancer proven by imaging examinations via multidisciplinary approaches according to NCCN guidelines;
- No prior chemotherapy or radiotherapy;
- ECOG of 0 or 1;
- Routine blood test: absolute neutrophil count>1500/mm3, platelet>100000/mm3;
- Normal liver function: serum total bilirubin≤2.0mg/dl, ALT and AST<2.5 times of the upper limit of normal value;
- Normal kidney function: serum creatinine<1.5 times of the upper limit of normal value or creatinine clearance rate>45ml/min;
- No severe comorbidities.
Exclusion Criteria:
- Metastatic pancreatic cancer;
- Patients who had surgeries, chemotherapy or other treatments before inclusion;
- Impaired organ functions: heart failure (New York Heart Association III-IV), coronary heart disease, myocardial infarction within 6 months, severe cardiac arrhythmia and respiratory failure;
- Confirmed other cancer within 5 years;
- Pregnant women or lactating women;
- Patients enrolled in other clinical trials or incompliant of regular follow up;
- Patients who did not provide an informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Group A of neoadjuvant chemotherapy
Neoadjuvant gemcitabine plus nab-paclitaxel is used in this group.
Intravenous administration of gemcitabine (1000mg/m2) and nab-paclitaxel (125 mg/m2) are initiated on day 1, 8 and 15 during each 4-week cycle, which will repeat for 3 cycles.
And surgical resection is performed after completion of the whole chemotherapy.
|
Neoadjuvant gemcitabine plus nab-paclitaxel is used in the intervention group for 3 cycles.
Standard doses of gemcitabine and nab-paclitaxel are adopted.
Surgical resection will be performed after neoadjuvant chemotherapy.
|
Experimental: Group B of neoadjuvant chemoradiotherapy
Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT is used in this group.
Intravenous administration of gemcitabine (1000mg/m2) and nab-paclitaxel (125 mg/m2) are initiated on day 1, 8 and 15 during each 4-week cycle, which will repeat for 3 cycles.
After completion of the whole chemotherapy, patients will first receive PET-CT to exclude distant metastases and then undergo SBRT.
The prescribed dose is 7.5-8Gy/f for 5 fractions.
Dose constraints of normal tissues are referred to the American Association of Physicists in Medicine guidelines in TG-101.
And surgical resection is performed 3 weeks after SBRT.
|
Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT is used in the intervention group for 3 cycles.
Standard doses of gemcitabine and nab-paclitaxel are adopted.
The radiation dose of SBRT is 7.5-8Gy/f for 5 fractions.
Surgical resection will be performed 3 weeks after SBRT.
|
Experimental: Group C of neoadjuvant chemoradiotherapy
Neoadjuvant S-1 plus nab-paclitaxel with SBRT is used in this group.
Intravenous administration of nab-paclitaxel (125 mg/m2) is initiated on day 1, 8 and 15 during each 4-week cycle, which will repeat for 3 cycles.
And S-1 is orally administrated at a dose of 80 mg/m2 for 18 days followed by a 10-day rest during each 4-week cycle, which aslo continues for 3 cycles.
After completion of the whole chemotherapy, patients will first receive PET-CT to exclude distant metastases and then undergo SBRT.
The prescribed dose is 7.5-8Gy/f for 5 fractions.
Dose constraints of normal tissues are referred to the American Association of Physicists in Medicine guidelines in TG-101.
And surgical resection is performed 3 weeks after SBRT.
|
Neoadjuvant S-1 plus nab-paclitaxel with SBRT is used in the intervention group for 3 cycles.
Standard doses of gemcitabine and nab-paclitaxel are adopted.
The radiation dose of SBRT is 7.5-8Gy/f for 5 fractions.
Surgical resection will be performed 3 weeks after SBRT.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall time
Time Frame: From date of randomization until the date of death from any cause, whichever came first, assessed up to 24 months
|
The time between operation and the death of patients
|
From date of randomization until the date of death from any cause, whichever came first, assessed up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease free time
Time Frame: From date of randomization until the date of first documented progression or metastasis, assessed up to 12 months
|
The time between operation and the relapse or metastasis of tumors
|
From date of randomization until the date of first documented progression or metastasis, assessed up to 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Gang Jin, Doctor, Changhai Hospital, Shanghai, China
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2019
Primary Completion (Estimated)
December 31, 2023
Study Completion (Estimated)
December 31, 2023
Study Registration Dates
First Submitted
December 14, 2018
First Submitted That Met QC Criteria
December 14, 2018
First Posted (Actual)
December 17, 2018
Study Record Updates
Last Update Posted (Actual)
September 1, 2023
Last Update Submitted That Met QC Criteria
August 31, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
- Albumin-Bound Paclitaxel
- Gemcitabine
Other Study ID Numbers
- ChanghaiH-PP04
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Cancer
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CelgeneWithdrawnPancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of NebraskaNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic Carcinoma | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedPancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer | Poorly Differentiated Malignant Neoplasm | Undifferentiated Pancreatic CarcinomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer
-
National Cancer Institute (NCI)CompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of Wisconsin, MadisonCompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Fudan UniversityUnknownStage ⅠA Pancreatic Cancer | Stage ⅠB Pancreatic Cancer | Stage ⅡA Pancreatic Cancer | Stage ⅡB Pancreatic CancerChina
-
University of UtahNovartis PharmaceuticalsRecruitingMetastatic Pancreatic Carcinoma | Unresectable Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic CancerUnited States
-
Shanghai Zhongshan HospitalFudan UniversityNot yet recruitingPancreatic Cancer Stage III | Pancreatic Cancer, Stage IB | Pancreatic Cancer, Stage IIA | Pancreatic Cancer, Stage IIBChina
Clinical Trials on Neoadjuvant gemcitabine plus nab-paclitaxel
-
HutchmedNot yet recruiting
-
Tata Memorial CentreRecruiting
-
Trishula Therapeutics, Inc.AbbVieRecruitingPancreatic CancerUnited States
-
AIO-Studien-gGmbHCelgene; ClinAssess GmbHCompletedResectable Pancreatic Cancer | Ductal Adenocarcinoma of the PancreasGermany
-
Wuhan Union Hospital, ChinaNot yet recruitingPancreatic Cancer | Pancreatic Cancer Non-resectable | Pancreatic Ductal Adenocarcinoma, PDACChina
-
Chinese PLA General HospitalUnknown
-
Wakayama Medical UniversityUnknown
-
PH Research, S.L.CompletedAdvanced Pancreatic CancerSpain
-
Chinese Society of Lung CancerCompletedCarcinoma, Non-Small-Cell LungChina
-
Chang Gung Memorial HospitalRecruitingMetastatic Pancreatic AdenocarcinomaTaiwan